203 related articles for article (PubMed ID: 8609411)
1. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
2. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
3. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
Fallarino F; Ashikari A; Boon T; Gajewski TF
Int Immunol; 1997 Sep; 9(9):1259-69. PubMed ID: 9310829
[TBL] [Abstract][Full Text] [Related]
5. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
6. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.
Horspool JH; Perrin PJ; Woodcock JB; Cox JH; King CL; June CH; Harlan DM; St Louis DC; Lee KP
J Immunol; 1998 Mar; 160(6):2706-14. PubMed ID: 9510170
[TBL] [Abstract][Full Text] [Related]
8. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
[TBL] [Abstract][Full Text] [Related]
9. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
Fallarino F; Uyttenhove C; Boon T; Gajewski TF
J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
[TBL] [Abstract][Full Text] [Related]
10. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
11. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
12. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
13. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
15. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.
Judge TA; Wu Z; Zheng XG; Sharpe AH; Sayegh MH; Turka LA
J Immunol; 1999 Feb; 162(4):1947-51. PubMed ID: 9973463
[TBL] [Abstract][Full Text] [Related]
16. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.
Yeh KY; Pulaski BA; Woods ML; McAdam AJ; Gaspari AA; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):217-24. PubMed ID: 7553886
[TBL] [Abstract][Full Text] [Related]
17. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK
J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945
[TBL] [Abstract][Full Text] [Related]
18. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
Sigal LJ; Reiser H; Rock KL
J Immunol; 1998 Sep; 161(6):2740-5. PubMed ID: 9743331
[TBL] [Abstract][Full Text] [Related]
19. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
20. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
